Does the Wegovy dose increase during treatment — and why?

What the approved titration schedule actually looks like

The Wegovy dose increase pathway is set out in the medicine's Summary of Product Characteristics, published on the electronic Medicines Compendium, and it follows a stepwise pattern: 0.25 mg for the first four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each step lasting approximately one month. The full dose increase chart sets this out clearly if you want a week-by-week view.

The reason for the gradual climb is straightforward. Semaglutide slows how quickly the stomach empties, and moving too fast up the dose ladder is the main driver of nausea, vomiting and stomach cramps in the early weeks. Starting at 0.25 mg gives your gut time to adapt. That dose has no meaningful appetite-suppressing effect on its own; its job is to prepare you for the doses that do. If you want to understand why increasing the Wegovy dose is done in stages rather than all at once, the answer comes down to how your gut adapts to semaglutide over time. Most people reach 2.4 mg around week 17, though there is nothing in the licence that penalises a slower journey if your prescriber judges it appropriate.

Since January 2026, a 7.2 mg dose has also been authorised by the MHRA, with a single-dose pen approved on 14 April 2026 for adults with a BMI of 30 or above. The titration to 7.2 mg still begins at 0.25 mg; the maximum dose is simply higher. Availability of specific pen formats and dose strengths is confirmed at consultation, not assumed in advance.

What the clinical evidence shows about higher doses and weight loss

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants taking semaglutide 2.4 mg lost an average of around 15% of their body weight, compared with roughly 2.4% in the placebo group. Those results were achieved because participants successfully reached and sustained the 2.4 mg maintenance dose, the dose increase schedule is the mechanism that makes the endpoint achievable.

Research into the 7.2 mg dose reported approximately 20.7% average weight loss over 72 weeks, approaching results seen with tirzepatide at its highest dose. Whether a higher maintenance dose is appropriate depends on individual clinical assessment, and our page covering how a Wegovy increase works in practice explains what that process involves. The relationship between dose and weight loss is worth reading alongside this page if that is your core question.

A question our prescribers hear most weeks is whether it is safe to push through side effects to reach the next dose sooner. The honest answer from the trial data is no. Tolerability problems that are not well managed at a lower dose tend to worsen after a step up, and there is no evidence that rushing the schedule produces meaningfully better outcomes.

When a dose increase is delayed or paused

Not every patient moves through the schedule at the textbook pace, and that is expected. The prescriber's role at each review is to weigh the benefits of moving up against your current side-effect burden. If nausea or diarrhoea has been persistent, staying at the current dose for an extra four weeks is a recognised clinical approach, not a failure of treatment. Knowing when to increase the Wegovy dose is a decision made with your prescriber, not a milestone you hit automatically.

NICE's appraisal of semaglutide, TA875, recommends stopping treatment if less than 5% weight loss has occurred after six months at the maintenance dose. That guidance applies to the NHS pathway, but it reflects a clinically important principle: the dose increase schedule exists to get you to an effective dose, and if the maintenance dose is not producing results, continuing indefinitely is not the right course. Your prescriber should be reviewing progress at each repeat, not simply renewing without assessment.

Missed doses and what to do when you have skipped an injection are covered in the Patient Information Leaflet rather than here. The right source for that guidance is the leaflet that comes with your medication, not a general webpage.

Private treatment and the dose increase process at nume

At nume, every repeat prescription involves a clinical review before anything is dispensed. A real prescriber, registered with the GPhC as an Independent Prescriber, reads your progress notes before each step up is authorised. There is no automated renewal and no algorithm making the call. If you have questions about how your treatment is going, our aftercare team is available seven days a week via the contact page.

For context on what private Wegovy treatment typically costs in the UK, the Wegovy price comparison page covers what different providers include in their pricing and what to look for. Our own treatment pricing is shown on the treatment page alongside the consultation process. If you'd like to talk through the schedule with one of our prescribers, the straightforward next step is to speak to our prescribers through a free consultation.